Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically confirmed solitary primary or recurrent papillary transitional cell carcinoma of the bladder~  * Ta or T1~* Tumor no greater than 2 cm in diameter~* Negative urine cytology~* No suspicious lesions in bladder requiring biopsy~* No tumors in the prostatic urethra or upper urinary tract~* No prior history of T1 G3 tumors, muscle invasive tumors (T2 or greater), or carcinoma in situ~PATIENT CHARACTERISTICS:~Age~* 80 and under~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* HIV negative~* No active intractable or uncontrollable bladder infection~* No urethral strictures that would preclude endoscopic procedures or repeated catheterization~* No prior or concurrent congenital or acquired immune deficiency syndrome~* No other prior or concurrent malignancy except cured basal cell skin cancer or intraepithelial cancer of the cervix~* No prior or concurrent leukemia or Hodgkin's disease~* No concurrent disease for which general anesthesia is contraindicated~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 12 months since prior BCG vaccine~Chemotherapy~* At least 1 year since prior mitomycin~Endocrine therapy~* Not specified~Radiotherapy~* No prior pelvic radiotherapy~Surgery~* No prior organ transplant~Other~* At least 3 months since prior intravesical treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).